News
OGEN
0.3558
-3.42%
-0.0126
Weekly Report: what happened at OGEN last week (1202-1206)?
Weekly Report · 2d ago
Weekly Report: what happened at OGEN last week (1125-1129)?
Weekly Report · 12/02 09:37
Weekly Report: what happened at OGEN last week (1118-1122)?
Weekly Report · 11/25 09:35
Weekly Report: what happened at OGEN last week (1111-1115)?
Weekly Report · 11/18 09:34
Earnings week ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and more
Seeking Alpha · 11/18 05:09
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 11/12 11:11
Weekly Report: what happened at OGEN last week (1104-1108)?
Weekly Report · 11/11 09:37
Weekly Report: what happened at OGEN last week (1028-1101)?
Weekly Report · 11/04 09:37
Weekly Report: what happened at OGEN last week (1021-1025)?
Weekly Report · 10/28 09:34
Weekly Report: what happened at OGEN last week (1014-1018)?
Weekly Report · 10/21 09:34
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Barchart · 10/18 07:30
Oragenics Shares Investor Presentation Online
TipRanks · 10/16 14:57
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 10/14 20:31
Weekly Report: what happened at OGEN last week (1007-1011)?
Weekly Report · 10/14 09:41
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/11 15:10
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/10 15:10
Oragenics provided update to shareholders
TipRanks · 10/09 11:41
Oragenics Provided A Corporate Update Reflecting On The Company's Progress Throughout 2024, Including Key Milestones In The Development Of ONP-002, Its Lead Candidate For Concussions
Benzinga · 10/09 11:34
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Barchart · 10/09 06:30
Oragenics completes key FDA-recognized study for ONP-002
TipRanks · 10/08 12:50
More
Webull provides a variety of real-time OGEN stock news. You can receive the latest news about Oragenics through multiple platforms. This information may help you make smarter investment decisions.
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its lead product and focus is on the development and commercialization of ONP-002 for the treatment of mTBI.